Genmab — September 2016
-
Vi glæder os
-
"
What they found was that daratumumab helped improve the tumor microenvironment by enhancing the immune response. So daratumumab actually reduced T-regulator cells, MDSCs and B-regulatory cells at the same time that it helped expand helper and cytotoxic T cells. The authors’ elegant work also showed that not only was there expansion of the effector and helper T cells, but there was also an increase of functional activity of these cells. These immune cells had more alloreactive functions and the -
alloreactive functions and the authors confirmed that these cells were clonal by using a T-cell clonality assay. So in this setting, what I see a similar thing as we see with immune checkpoint inhibitors, which is immune enhancement.
-
"f this antibody is mobilizing the immune system in a way that it reduces the B- and T-regulatory cells [that inhibit T-cell function] and MDSCs, whether it can be another immune checkpoint inhibitor and whether we can combine it with other antibodies or cytotoxic therapies in various other solid tumors is [an open question]. I see that in the future we will see these types of studies with daratumumab".
-
Vi begynder at ane, hvorfra Jan van de Winkels selvtillid stammer fra.
-
Jeg nævner: Keytruda, Opdivo, Tecendriq og Yervoy http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/immunotherapy/cancer-immunotherapy-immune-checkpoint-inhibitors
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind